β-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): A randomized dose-ranging trial

Pharmacotherapy

Volumn 29, Issue 8, 2009, Pages 883-890

  Zebrack, James S ^a   Munger, Mark ^a,b   MacGregor, John ^a   Lombardi, William L ^c   Stoddard, Gregory P ^a   Gilbert, Edward M ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c North Cascade Cardiology   (United States)

Author keywords

blockers; receptor selectivity; Heart failure; Pharmacology

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL SUCCINATE; POTASSIUM; SPIRONOLACTONE; TERBUTALINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG SELECTIVITY; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; MAXIMUM TOLERATED DOSE; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-2 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; BLOOD GLUCOSE; CARBAZOLES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HEART FAILURE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; POTASSIUM; PROPANOLAMINES; TERBUTALINE;

EID: 68149157172     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.8.883     Document Type: Article

References (35)

1. The CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol trial II (CIBIS-II): a randomized trial. Lancet 1999;353:9-13.
2. The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-2007.
3. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET). Lancet 2003;362:7-13.
4. 2-adrenoceptor stimulant be used to assess the selectivity of β-adrenoceptor blockers? Br J Clin Pharmacol 1983;16:557-560
5. 2-Adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 2000;101:71-77
6. 2-adrenergic receptor stimulation in dogs susceptible to lethal arrhythmias. J Appl Physiol 2001;91:1627-1637
7. Johnansson BW. Effect of β-blockade on ventricular fibrillation- and ventricular tachycardia-induced circulatory arrest in acute myocardial infarction. Am J Cardiol 1986;57:F34-7.
8. 1-receptor? A perspective on the results of the COMET trial. J Card Fail 2003;9:429-443
9. Wikstrand J, Ajalmarson A, Waagwstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002;40:491-498 (Pubitemid 34833165)
10. Engelmeier RS, O'Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72:536-546 (Pubitemid 15242247)
11. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. A 3-year follow-up of patients randomized in the metoprolol in dilated cardiomyopathy trial. Lancet 10998;351:1180-1181
12. Wiklund I, Waagstein F, Swedberg K, Hjalmarsson A. Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial: metoprolol in dilated cardiomyopathy trial. Cardiovasc Drugs Ther 1996;10:361-368
13. Andersson B, Hamm C, Persson S, et al. Improved exercise hemodynamic status in dilated cardiomyopathy after β-adrenergic blockade treatment. J Am Coll Cardiol 1994;24:1310-1320 (Pubitemid 24158009)
14. Kendall M, Akhlaghi S, Hughes B, Lewis H. Is metoprolol CR/ZOK more selective than conventional metoprolol and atenolol? J Clin Pharmacol 1990;30:S98-102.
15. Sankoh AJ, Hugue MF, Dubey SD. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Statist Med 1997;16:2529-2542
16. Freeman K, Lerman I, Kranias E, et al. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest 2000;107:967-974 (Pubitemid 32323407)
17. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-2825 (Pubitemid 26411746)
18. 1-selective and nonselective β-adrenergic receptor blockade of cardiac sympathetic activity in congestive heart failure. Circulation 1996;94:353-358
19. Azevedo ER, Kubo T, Mak S, et al. Nonselective versus selective β-adrenergic receptor blockade in congestive heart failure. Circulation 2001;104:2194-2199
20. Latini R, Masson S, Anand I, et al, for the Val-HeFT Investigators. The comparative prognositic value of plasma neurohormones at baseline in patients with heart failure enrolled in the Val-HeFT. Eur Heart J 2004;25:292-299 (Pubitemid 38295437)
21. Bristow MR, Feldman AM, Adams KF, Goldstein S. Selective versus nonselective β-blockade for heart failure therapy: Are there lessons to be learned from the COMET trial? J Card Fail 2003;9:444-453
22. Bristow MR, Abraham WT, Yoshikawa T, et al. Second- and third-generation β-blocking drugs in chronic heart failure. Cardiovasc Drugs Ther 1997;11(suppl 1):291-296 (Pubitemid 27229326)
23. Witchitz S, Cohen-Solal A, Dartois N, Weisslinger N, Juste K, Darmon JY, for the CELICARD Group. Treatment of heart failure with celiprolol, a cardioselective β-blocker with β2- agonist vasodilatory properties. Am J Cardiol 2000;85:1467-1471 (Pubitemid 30336584)
24. Sanderson JE, Chan SKW, Yu CM, et al. β-Blockers in heart failure: a comparison of a vasodilating β-blocker with metoprolol. Heart 1998;79:86-92. (Pubitemid 28179071)
25. 2-Adrenergic receptor polymorphisms influence the effects of carvedilol in the patients with chronic heart failure [abstract]. Eur J Heart Fail 2007;6(suppl 1):100.
26. Packer M, Antonopoulos GV, Berlin JA, Chittams J, Knostam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001;141:899-907. (Pubitemid 32477000)
27. Packer M, Bristow MR, Cohn JN, et al, for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355
28. Packer M, Fowley MB, Roecker EB, et al, for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-2199 (Pubitemid 35222212)
29. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001;357:1385-1390 (Pubitemid 32455364)
30. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Lancet 1997;349:375-380
31. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446 (Pubitemid 24000287)
32. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-2997
33. Heart Protection Collaborative Study Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22. (Pubitemid 34756487)
34. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of β-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000;102:546-551 (Pubitemid 30642529)
35. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-2816